Neuromodulation, Ketamine, and MDMA in Borderline Personality Disorder
September 29, 2026 DOI: 10.64239/pi-vl11210 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary |
|---|---|
| Interventions | Ketamine MDMA-assisted psychotherapy |
| Topics | Esketamine Ketamine MDMA |
| Key points | The author argues that neuromodulation may serve a supplementary role for BPD patients with comorbid major depression who have failed other treatments, citing systematic review evidence. The text cautions that ketamine use in BPD requires monitoring for disinhibited behaviors and increased suicidal ideation, both documented as negative reactions in case reports, and notes that MDMA-assisted psychotherapy has not been studied in BPD and would likely need modified protocols. |
Abstract
Consider neuromodulation for BPD patients with comorbid major depression who have failed antidepressants and other medications. Systematic review evidence supports a supplementary role in these cases. When using ketamine in BPD, monitor carefully for disinhibited behaviors and increased suicidal ideation. Case reports have documented both as negative reactions. MDMA-assisted psychotherapy has not been studied in BPD. Standard protocols would likely need significant modification for this population.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
State of the evidence: MDMA Unclear
Argues that MDMA-assisted psychotherapy has not been studied in borderline personality disorder and that standard protocols would likely need significant modification.
Synthesized